Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF^V600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.

ABSTRACT: Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma. Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically. In the non-comparative, randomized, phase 2 NeoTrio trial, we investigated whether targeted therapy could boost the proportion of patients achieving long-term recurrence-free survival with neoadjuvant immunotherapy in resectable stage III BRAF^V600-mutant melanoma. Sixty patients (42% females) were randomized to pembrolizumab alone (n = 20), sequential therapy (dabrafenib plus trametinib followed by pembrolizumab; n = 20) or concurrent (triple) therapy (n = 20), followed by surgery and adjuvant therapy. The primary outcome was pathological response; secondary outcomes included r

SUBMITTER: Long GV 

PROVIDER: S-EPMC11405264 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature